Jun 11, 2020 / 01:40PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD
Good morning, everybody. Thank you for joining us. I'm Terence Flynn, the Biopharma Analyst at Goldman Sachs. We're very pleased to have Alkermes joining us this morning for our virtual conference. From the company, we have Richard Pops, Chairman and CEO; and Sandy Coombs, Vice President of Investor Relations. Thank you both for taking time this morning to be with us. Really appreciate it.
And first, I'm going to turn it over to Rich for some opening remarks before we go into the fireside chat.
Richard F. Pops - Alkermes plc - Chairman & CEO
Well, good morning, Terence, and good morning, everybody. I won't take long. I'll just say a couple of things that are top of mind for me. One is, at this moment in time, which is this interesting confluence of COVID-19, along with significant civil unrest under -- over about racial disparities in the U.S. It's a moment to remind the world the importance of the biopharmaceutical industry. And in our particular case, in Alkermes case and our
Alkermes Plc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers